Aktuální léčba virových hepatitid.
|Title in English||Current viral hepatitis therapy.|
|Year of publication||2020|
|Type||Article in Periodical|
|Magazine / Source||Acta medicinae|
|MU Faculty or unit|
|Keywords||hepatitis A-E; tenofovir; entecavir; sofosbuvir; ledipasvir; velpatasvir; voxilaprevir; glecaprevir; pibrentasvir; elbasvir; grazoprevir|
|Description||The treatment of acute viral hepatitis, which takes place during hospitalizations in infectious diseases and clinics, usually does not differ according to the types of viral hepatitis and is usually only symptomatic. Oral antivirals are indicated only for severe or prolonged acute hepatitis B. In the case of a fulminant course of acute hepatitis E, ribavirin is the empirically administered drug of choice for chronic hepatitis E. At present, the vast majority of chronic hepatitis B patients in Europe are including the Czech Republic, treated with tenofovir or entecavir. Treatment of chronic hepatitis C with combinations of direct-acting oral antivirals (DAAs) has high efficacy (up to 100%), minimal contraindications and an extremely favorable safety profile. Hepatitis D is very rare in the Czech Republic, it is treated with pegylated interferon alfa.|